Abstract: Objective To explore the efficacy and safety of intraperitoneal injection of recom-binant human endostatin (endostar)combined with cisplatin in the treatment of malignant peritoneal effusion.Methods 86 patients were randomly divided into trial group (intraperitoneal injection of en-dostar combined with cisplatin)and control group (intraperitoneal injection of cisplatin alone).Clini-cal efficacy,adverse reactions and the quality of life (QOL)of the patients were compared between two groups.Results The overall response rate (ORR)in trial group was significantly higher than con-trol group,and disease control rate (DCR)was higher than control group,but there was no significant difference.The ORR in patients with bloody peritoneal effusion was significantly higher than control group,and ORR in patients with non -bloody peritoneal effusion was slightly higher than control group.Conclusion Efficacy of intraperitoneal infusion of endostar combined with cisplatin is better than cisplatin,especially for the patients with bloody malignant ascites,and it won′t cause severe ad-verse reactions,so it is worthy of clinical application and popularization.